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1. Introduction 
Chronic kidney disease is a very real and growing problem, as indicated by demographic 
trends. The total number of treated patients has markedly increased during the last 30 years, 
and chronic kidney disease currently affects approximately 19 million adult Americans, 
with an incidence that is still increasing (Snyder & Pendergraph, 2005). This trend is caused 
by a growing percentage of elderly people in the population as well as by technical progress 
and broader availability of dialysis therapy. An increasing number of diabetic patients is a 
further important factor. 
Chronic kidney disease is characterized by progressive deterioration of kidney function, 
which develops eventually into a terminal stage of chronic kidney failure. Chronic kidney 
failure has traditionally been categorized as mild, moderate, or severe. Other poorly defined 
terms like uremia and end-stage renal disease have commonly been applied. During the last 
few years, an international consensus has emerged categorizing chronic kidney failure into 5 
stages according to the glomerular filtration rate (GFR) and presence of signs of kidney 
damage: stage 1: GFR > 90 ml/min and signs of kidney damage; stage 2: GFR = 60–89 
ml/min and signs of kidney damage; stage 3: GFR = 30–59 ml/min; stage 4: GFR = 15–29 
ml/min; and stage 5: GFR < 15 ml/min (Levey et al., 2005). RIFLE (from Risk, Injury, 
Failure, Loss, End Stage) is a modern classification of acute renal failure and it is noteworthy 
here (Van Biesen et al., 2006). 
Stage 5 of chronic kidney failure represents the total inability of kidneys to maintain 
homeostasis, and this metabolic state is without treatment incompatible with life. Thus, at 
this stage, it is necessary to use methods that substitute for kidney function to ensure patient 
survival; these methods include hemodialysis, peritoneal dialysis, and other extracorporeal 
purifying procedures, or kidney transplantation. 
Chronic kidney failure is associated with many kinds of metabolic changes caused by the 
kidney disease itself and also attributable to dialysis treatment. Phenomena such as 
accumulation or deficit of various substances and dysregulation of metabolic pathways 
participate and combine in the pathogenesis of these changes. In the process of 
accumulation, decreased urinary excretion plays a crucial role and leads to retention of 
metabolites in the organism (e.g., creatinine, urea, electrolytes, water, substances with 
middle molecular weight such as beta-2 microglobulin and other). The increased formation 
of metabolites through catabolic processes and alternative metabolic pathways also wields 
an influence. Regular dialysis treatment partly decreases this accumulation but cannot avert 
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the overall deficit. The deficit of some important substances in chronic kidney failure can be 
caused by deficient intake in diet, impaired intestinal absorption, or increased losses during 
dialysis sessions. Disturbed synthesis of some crucial metabolic regulators (e.g., 
erythropoietin or active vitamin D) in kidneys also plays an important role (Cibulka & 
Racek, 2007). 
All of the abovementioned factors lead to many serious complications for patients with 
chronic kidney disease during the course of predialysis and dialysis. All markedly affect 
prognosis and the quality of life of these patients. 
Metabolic complications of chronic kidney failure and hemodialysis include basically 
changes in acid-base balance and changes in metabolism of proteins, carbohydrates and 
lipids. Furthermore, we describe disorders typical for chronic kidney disease such as renal 
anemia, bone mineral disease, atherosclerosis and cardiovascular disease, oxidative stress, 
dialysis-related amyloidosis, hyperhomocysteinemia and endothelial dysfunction. 
2. Acid–base balance  
Acid-base disorder is commonly observed in the course of chronic kidney failure. 
Metabolic acidosis is noted in a majority of patients when GFR decreases to less than 25% of 
normal. The degree of acidosis approximately correlates with the severity of chronic kidney 
failure and usually is more severe at a lower GFR. Metabolic acidosis can be of the high-
anion-gap type, although anion gap can be normal or only moderately increased even with 
stages 4 or 5 of chronic kidney failure (Kraut & Kurtz, 2005). In mild chronic renal 
insufficiency, metabolic acidosis is the result of a reduced ability to reabsorb bicarbonate, to 
excrete ammonia, and to eliminate titratable acid excretion (hyperchloremic, normal anion 
gap acidosis). In more severe renal insufficiency, organic and other conjugate anions of acids 
(nonvolatile acids) cannot be sufficiently excreted, and elevated anion gap acidosis appears 
(Kovacic et al., 2003). 
Metabolic acidosis resulting from advanced chronic kidney failure is called uremic acidosis. 
The level of GFR at which uremic acidosis develops varies depending on a multiplicity of 
factors. Endogenous acid production is an important factor, which in turn depends on the 
diet. Ingestion of vegetables and fruits results in net production of alkali, and therefore 
increased ingestion of these foods will tend to delay the appearance of metabolic acidosis in 
chronic renal failure. Diuretic therapy and hypokalemia, which tend to stimulate ammonia 
production, may delay the development of acidosis. The etiology of the renal disease also 
plays a role. In predominantly tubulointerstitial renal diseases, acidosis tends to develop 
earlier in the course of renal insufficiency than in predominantly glomerular diseases. In 
general, symptomatic metabolic acidosis is rare when the GFR is greater than 25–20 ml/min 
(Oh et al., 2004). 
Several adverse consequences have been associated with uremic acidosis, e.g. muscle 
wasting, bone disease, abnormalities in growth hormone and thyroid hormone secretion, 
impaired insulin sensitivity, and exacerbation of beta-2 microglobulin accumulation (Kraut 
& Kurtz, 2005). Other complications include negative nitrogen balance, anorexia, fatigue, 
impaired function of the cardiovascular system, hyperkalemia, and altered gluconeogenesis 
and triglyceride metabolism (Kovacic et al., 2003). 
Therapy of uremic acidosis should aim to obtain a serum bicarbonate level as close to 
normal as possible (i.e., 22–26 mmol/l). The best way to initiate therapy is with oral sodium 
bicarbonate (1 tablet three times a day) and to increase the dosage as necessary. The usual 
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tablet of 650 mg of sodium bicarbonate contains 7.5 mmol of alkali (HCO3- ions). 
Occasionally patients treated with sodium bicarbonate complain of gastric discomfort. In 
this case, they may use Shohl’s solution (a mixture of sodium citrate and citric acid). In 
dialysis patients, the treatment of acidosis relies on the gain of alkali from the dialysate 
either as bicarbonate in hemodialysis or as lactate in peritoneal dialysis (Oh et al., 2004). 
3. Protein metabolism 
Patients with chronic kidney disease in predialysis stages have to keep a low-protein diet to 
protect kidneys against hyperfiltration and following progression of chronic kidney disease. 
On the other hand, a too-strict low-protein diet can have a negative effect on nitrogen 
balance. A safe low-protein diet should contain 0.6 g of protein/kg/day, minimally. 
Disorders in protein metabolism in hemodialysis patients are usually caused by combined 
(protein and energy) malnutrition that can be termed uremic malnutrition. It is present in 
approximately 20%–50% of patients on dialysis and is characterized by insidious loss of 
somatic protein stores (reflected in lean body mass and serum creatinine) and visceral 
protein concentrations (reflected in serum albumin and prealbumin concentrations) (Ikizler, 
2004). Urinary losses of protein and losses of amino acids during a dialysis session may play 
a role as well. Metabolic acidosis is a further important factor that markedly contributes to 
negative nitrogen and total body protein balance in patients with chronic kidney failure 
(Kovacic et al., 2003). 
It has been demonstrated that the presence of uremic malnutrition increases mortality and 
morbidity in chronic dialysis patients (Ikizler et al., 1999). It is very often combined with a 
chronic inflammation state in the syndrome known as malnutrition-inflammation complex 
syndrome (Kalantar-Zadeh et al., 2003). Chronic inflammation accelerates the catabolism 
and deepens the negative nitrogen balance. The malnutrition-inflammation score (MIS) is a 
number from 0 to 30 by which an outcome of a dialysis patient can be estimated. Its 
calculation includes seven components of subjective global assessment, body mass index, 
and serum albumin and transferrin concentrations. Higher value of MIS indicates worse 
outcome of a patient (Rambod et al., 2009). 
4. Carbohydrate metabolism 
Disorders of carbohydrate metabolism are very frequent in patients with chronic kidney 
failure. On the one hand, diabetes mellitus is the most common cause of kidney failure. 
Diabetics represent about 35% of all dialyzed patients. In these cases, the causality seems to 
be relatively clear. 
On the other hand, a majority of dialyzed patients are not diabetics. But also non-diabetics 
patients with chronic kidney disease have often disorders of carbohydrate metabolism. 
Impaired glucose tolerance occurs together with the loss of kidney function (Alvestrand, 
1997). Insulin resistance is primarily detectable when GFR is below 50 ml/min. Reduced 
insulin-mediated non-oxidative glucose disposal is the most evident defect of glucose 
metabolism, but impairments of glucose oxidation, the defective suppression of endogenous 
glucose production, and abnormal insulin secretion also contribute to uremic glucose 
intolerance (Rigalleau & Gin, 2005). Accumulating nitrogenous uremic toxins seem to be the 
dominant cause of a specific defect in insulin action, and identification of these toxins is 
progressing, particularly in the field of carbamoylated amino acids. The consequences of 
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chronic kidney failure, such as exercise intolerance, anemia, metabolic acidosis, secondary 
hyperparathyroidism, or insufficient activation of vitamin D, also indirectly play a role 
(Rasic-Milutinovic et al., 2000). 
It has been reported that insulin resistance may be related to arterial hypertension 
(Ferrannini et al., 1987) and may contribute to high cardiovascular morbidity and mortality 
in patients with chronic kidney failure (Shinohara et al., 2002). The underlying mechanism 
can be an impaired synthesis of nitric oxide (NO) in endothelium of patients with chronic 
kidney disease. It was proved that appropriately functioning endothelial NO synthase is 
important for the control not only of arterial pressure but also of glucose and lipid 
homeostasis (Duplain et al., 2001). 
Disturbance in synthesis of adipocytokines may contribute to the insulin resistance and 
related metabolic disorders in patients with chronic kidney failure. Patients with metabolic 
syndrome have lower levels of adiponectin and, on the contrary, higher levels of leptin than 
patients without metabolic syndrome (Vostry et al., 2008). 
5. Lipid metabolism 
Lipid metabolism appears to be substantially influenced by the severity of renal 
dysfunction. 
Patients with chronic kidney disease have elevated levels of triglycerides mainly because of 
enhanced production of triglyceride-rich lipoproteins such as very-low-density lipoproteins 
(VLDL) in the liver (Attman et al., 1993). Further reasons are decreased activities of hepatic 
lipase and peripheral lipoprotein lipase. These abnormalities in turn may be due to an 
inhibitory effect of hyperparathyroidism, calcium accumulation in islet cells resulting in 
impaired insulin action, elevated level of apolipoprotein C-III which acts as a direct lipase 
inhibitor, or a putative circulating inhibitor detected in uremic plasma (Shurraw & Tonelli, 
2006). Hyperinsulinemia is, however, probably the main factor increasing synthesis of 
triglycerides and directly decreases activity of lipoprotein lipase. 
Insufficient mitochondrial beta-oxidation, due to a deficit of L-carnitine, is an important 
factor for the development of disorder in lipid metabolism in hemodialysis patients. L-
carnitine is an essential substance for transport of long chain fatty acids across the inner 
mitochondrial membrane into mitochondrial matrix where beta-oxidation proceeds 
(Cibulka et al., 2005). 
Following changes in lipid metabolism are also found in many patients with chronic kidney 
failure. The most prominent are increased serum triglyceride levels mentioned above and 
low levels of high-density lipoprotein (HDL) cholesterol. Low-density lipoprotein (LDL) 
cholesterol levels are often normal, but the cholesterol may originate from the atherogenic 
small and dense LDL subclass. The apolipoprotein B-containing lipoprotein particles may 
undergo modifications (peptide modification of the enzymatic and advanced glycation end-
product, oxidation, or glycation). Modifications contribute to impaired LDL receptor-
mediated clearance from plasma and promote prolonged circulation. HDL particles are 
structurally altered during states of inflammation (Cibulka & Racek, 2007). 
The contribution of this complex atherogenic form of dyslipidemia to cardiovascular disease 
in patients with chronic renal disease is not absolutely clear. Some studies reported negative 
results regarding the predictive power of serum lipids for the development of 
cardiovascular disease in these patients (Wanner & Krane, 2002). Recent findings have 
suggested that the development of malnutrition-inflammation complex syndrome is 
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responsible for this phenomenon. Because malnutrition-inflammation complex syndrome 
leads to a low body mass index, hypocholesterolemia, hypohomocysteinemia, and other 
manifestations, a reverse epidemiology of traditional cardiovascular risk factors occurs in 
patients with chronic kidney failure (Kalantar-Zadeh et al., 2003). It means that for example 
hypercholesterolemia, obesity or hyperhomocysteinemia appear to be protective and 
paradoxically associated with a better outcome. 
It is well known that HDL cholesterol level is inversely correlated with the risk of 
atherosclerosis. In addition to its role in reverse cholesterol transport, HDL has the ability to 
protect LDL particles against oxidation. The underlying mechanism by which HDL inhibits 
LDL oxidation is partly enzymatic. There is increasing evidence that paraoxonase 1 could be 
involved in this process (Mackness et al., 1993). It was proved that serum paraoxonase 1 
activity is reduced in patients with chronic kidney failure. The possible causes can include 
reduced HDL level, altered HDL subfraction distribution, reduced paraoxonase 1 
concentration and its different phenotype distribution. Another possible explanation could 
be that paraoxonase 1 activity is inhibited in the uremic environment. Generally, reduced 
serum paraononase 1 activity could also contribute to the accelerated development of 
atherosclerosis in patients with chronic kidney failure (Dirican et al., 2004). 
Lipoprotein (a) has been identified as an independent risk factor for atherosclerotic 
cardiovascular disease. It was found to be consistently elevated in a considerable proportion 
of patients with chronic kidney disease. Plasma concentration of lipoprotein (a) is highly 
heritable and mainly determined by a size polymorphism of apolipoprotein (a). It has been 
demonstrated that the low-molecular-weight apolipoprotein (a) phenotype independently 
predicted coronary artery disease occurrence (Kronenberg et al., 1999). It has been suggested 
that the apolipoprotein (a) size and the lipoprotein (a) plasma concentration may play a 
synergistic role in advanced atherosclerosis. 
Patients treated with peritoneal dialysis have a similar but more severe dyslipidemia 
compared to hemodialysis patients due to stimulation of hepatic lipoprotein synthesis by 
glucose absorption from dialysate, increased insulin levels, and selective protein loss in 
dialysate analogous to the nephrotic syndrome (Shurraw & Tonelli, 2006). 
6. Renal anemia 
Renal anemia, which is often associated with fatigue and cognitive and sexual dysfunction, 
has a significant impact on the quality of life of patients with chronic kidney failure. Anemia 
has been identified as an important etiologic factor in the development of left ventricular 
hypertrophy, an independent risk factor for heart failure and a predictor of mortality in 
hemodialysis patients (Cibulka & Racek, 2007). 
The major cause of renal anemia in patients with chronic kidney disease is an inadequate 
production of the glycoprotein hormone erythropoietin because of a reduction in functional 
kidney parenchyma (Santoro, 2002). Furthermore, free radicals elicited from leucocytes by 
their contact with the dialysis membrane cause hemolysis with consecutive anemia in 
patients on extracorporeal renal replacement therapy (Eiselt et al., 1999). There are a number 
of other metabolic derangements associated with uremia that can affect the production and 
survival of red blood cells (e.g., uremic toxins, parathormone, protein malnutrition) 
(Cibulka & Racek, 2007). 
The introduction of recombinant human erythropoietin has revolutionized the treatment of 
anemia in patients with chronic kidney failure. The majority of patients respond very well, 
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however, about 10% of patients show some resistance to this therapy. The most common 
causes of that are considered iron deficiency (Santoro, 2002) and the development of 
malnutrition-inflammation complex syndrome (Kalantar-Zadeh et al., 2003). The 
erythropoietin hyporesponsiveness can further worsen symptoms that decrease the quality 
of life, such as an intolerance of physical work, deterioration of cognitive functions, 
anorexia, insomnia, or depression. 
These problems are partly related to the deficit of L-carnitine mentioned above. In 
hemodialysis patients, a complex of complications related to the deficit of this important 
substance is marked as dialysis-related carnitine disorder. This disorder is a functional 
metabolic deficiency which can have a negative impact on erythrocyte production and 
survival. Laboratory studies examining the influence of L-carnitine on red blood cell 
function and clinical trials in hemodialysis patients support the use of L-carnitine in the 
setting of erythropoietin hyporesponsiveness (Golper et al., 2003). 
The supplementation with iron in patients with chronic kidney disease might obviate or 
delay the need for treatment with erythropoietin. Oral iron is inferior to intravenous iron in 
patients on hemodialysis, in part because elevated serum levels of hepcidin prevent 
intestinal absorption of iron. Increased levels of hepcidin, a peptide hormone produced by 
the liver, also impair the normal recycling of iron through the reticuloendothelial system 
(Besarab & Coyne, 2010). 
7. Bone mineral disease 
Bone mineral disease or renal osteodystrophy are terms which are used to describe the 
skeletal abnormalities of many patients with chronic kidney disease. 
Bone mineral disease is basically a multifactorial disorder of bone remodeling. It 
encompasses a heterogeneous group of disorders from states of high bone turnover to states 
of low bone turnover. High-turnover bone disease or osteitis fibrosa represents the 
manifestations of secondary hyperparathyroidism on bone. Low bone turnover syndromes 
are represented by the increasingly prevalent adynamic bone disease or less commonly, by 
osteomalacia. These disorders may occur in combination or alternately, each may 
predominate in any given patient (Gonzalez & Martin, 2001). 
The most important factor which is responsible for the development of secondary 
hyperparathyroidism is a deficit of active vitamin D (calcitriol). Diseased kidneys cannot 
sufficiently hydroxylate 25-hydroxycholecalciferol, which is a precursor of calcitriol (1,25-
dihydroxycholecalciferol). The deficit of calcitriol causes an inadequate absorption of 
calcium in the small intestine, with resulting hypocalcemia. Retention of inorganic 
phosphate may deteriorate this situation because phosphates impair the activity of 1-alpha-
hydroxylase even more. Long-lasting hypocalcemia and coincidental hyperphosphatemia 
lead to the stimulation of parathyroid glands with subsequent secondary 
hyperparathyroidism which causes decalcification of bones (Cibulka et al., 2007). Chronic 
metabolic acidosis intensifies this harmful process (Kraut and Kurtz, 2005). All of these 
factors are closely interrelated, and while one or more of them may predominate in a 
particular patient during the course of chronic kidney failure, much overlap occurs 
(Gonzalez and Martin, 2001). 
Moreover, hyperphosphatemia has been recognized as an important risk factor for 
cardiovascular disease mortality in patients with chronic kidney failure. It is a direct cause 
of vascular calcification, the cardio-bone connection (Lund et al., 2006). 
The treatment of vitamin D deficiency when present in patients with chronic kidney disease 
is warranted since such therapy may reduce or prevent secondary hyperparathyroidism in 
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the early stages. In patients with chronic kidney disease and GFR of 20 to 60 ml/min, 
nutritional vitamin D deficiency and insufficiency can both be prevented by 
supplementation with vitamin D2 (ergocalciferol) or vitamin D3 (cholecalciferol). The 
recommended daily allowance in individuals over 60 years is 800 IU, and for younger adults 
400 IU. In patients in stage 5 of chronic kidney failure and in those on dialysis, the value of 
supplementation is less certain; although in dialysis-dependent patients, high doses of 
ergocalciferol or 25-hydroxycholecalciferol can raise the serum levels of calcitriol (National 
Kidney Foundation, 2004). Calcitriol himself and 1-alpha-hydroxylated derivate of calcitriol 
(alphacalcidiol) are also commonly used for supplementation in clinical practice. 
In hemodialysis patients, the administration of L-carnitine may also have some positive 
effects on bone metabolism. It probably increases production of osteoprotegerin which is 
one of the most important regulators of osteoclastogenesis. Osteoprotegerin is a tumor 
necrosis factor-related cytokine which is produced by osteoblasts. It suppresses bone 
resorption and increases the density, area and strength of bone (Cibulka et al., 2007). 
8. Atherosclerosis and cardiovascular disease 
Cardiovascular disease is the leading cause of death in patients with chronic kidney failure. 
For every registry reporting national dialysis data in Europe, the U.S., Japan, and elsewhere, 
about 50% of deaths are attributed to cardiovascular disease. In comparison with the general 
population, dialysis patients have a greater than 20-fold increased risk of a cardiovascular 
death (Levey & Eknoyan, 1999). A majority of these deaths are related to atherosclerosis 
with subsequent myocardial infarction, cerebrovascular accidents (strokes), and ischemic 
events of the limbs. Additionally, patients with chronic kidney disease exhibit evidence of 
early and exaggerated vascular and cardiac remodeling (arteriosclerosis and left ventricular 
hypertrophy). The risk of cardiovascular disease and associated mortality increases in 
proportion to the decrease of GFR. It is significantly higher if GFR has fallen below 
approximately 75 ml/min. The evidence suggests that the damage is already far progressed 
when patients reach end-stage renal disease; thus, effective intervention must be started 
much earlier (Diaz-Buxo & Woods, 2006). Patients with albuminuria and normal GFR also 
are at increased risk (Go et al., 2004). 
Evaluation of traditional risk factors, including lipid levels, blood pressure, smoking, and 
sedentary lifestyle, is essential (Snyder & Pendergraph, 2005). 
The KDOQI (Kidney Disease Outcomes Quality Initiative) recommended a blood pressure 
goal of 130/80 mmHg in patients with normal urinary albumin concentrations, and a blood 
pressure goal of 125/75 mmHg in patients with excretion of more than 1 g of protein/24 
hours (National Kidney Foundation, 2002). 
The KDOQI guidelines on managing dyslipidemias in patients with chronic kidney disease 
recommended an LDL cholesterol goal of less than 100 mg/dl (2.60 mmol/l) (National Kidney 
Foundation, 2006). We use statins at moderate doses for reduction of LDL cholesterol levels. 
However, as mentioned above, some patients with chronic kidney disease with the lowest 
cholesterol levels are the most likely to die of cardiovascular disease because low levels of 
cholesterol are associated with nontraditional cardiac risk factors of malnutrition and 
inflammation (Liu et al., 2004). Additional cardiac risk factors specific to chronic kidney failure 
may also play an important role in the development of atherosclerosis. Among these factors 
we include for example volume overload, hyperparathyroidism, uremia, anemia, endothelial 
dysfunction, and, especially in hemodialysis patients, oxidative stress (Cibulka & Racek, 2007). 
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Statins probably influence, except the LDL cholesterol levels, still other cardiovascular risk 
factors, namely the chronic inflammation state. It is manifested as a decrease of C-reactive 
protein level. Large observational studies demonstrate that statin treatment is associated 
with a significant reduction of mortality in dialysis patients (Shurraw & Tonelli, 2006). 
9. Oxidative stress 
Oxidative stress is a state in which the production of reactive oxygen species exceeds the 
capacity of the antioxidant defense system in cells and tissues. Reactive oxygen species are 
free radicals, highly reactive substances with an unpaired electron in the outer orbital, and 
other related reactive compounds (such as hydrogen peroxide and hypochlorous acid) that 
can attack lipids, proteins, and nucleic acids and alter the structure and function of these 
macromolecules (Klaunig et al., 1998). Specifically, LDL particles are damaged by excessive 
oxidation and consequently are not recognized by cell LDL receptors. They are subsequently 
accumulated in the blood in higher amounts and penetrate the vascular walls. This 
mechanism is probably the basis of atherosclerotic lesions. 
Oxidative stress threatens hemodialysis patients with serious clinical complications (e.g., 
accelerated atherosclerosis, amyloidosis, hemolysis, and the development of the state of 
chronic inflammation). Free radicals originate from leucocytes, which are activated during 
the contact with the dialysis membrane, and also from erythrocyte iron released as a 
consequence of hemolysis (Eiselt et al., 1999). Intravenous administration of iron can also 
contribute to oxidative stress, increasing free radical production by the so-called Fenton 
reaction. Co-administration of ascorbic acid with the goal of mobilizing iron stores further 
stimulates free radical formation, possibly by reduction of Fe(III) ions to more dangerous 
Fe(II) compounds (Eiselt et al., 2006). 
10. Dialysis-related amyloidosis 
Dialysis-related amyloidosis is a frequent complication of chronic kidney failure and long-
term renal replacement therapy. Beta-2 microglobulin is a major constituent of amyloid fibrils. 
Amyloid deposition mainly involves bone and joint structures, presenting as carpal tunnel 
syndrome, destructive arthropathy, and subchondral bone erosions and cysts. The molecular 
pathogenesis of this complication remains unknown. Recent studies, however, have suggested 
a pathogenic role of a new modification of beta-2 microglobulin in amyloid fibrils. Increased 
carbonyl compounds derived from autoxidation of both carbohydrates and lipids modify 
proteins in uremia, leading to augmentation of advanced glycation end-products and 
advanced lipoxidation end-product production. Thus, uremia might be a state of carbonyl 
overload with potentially damaging proteins (carbonyl stress) (Miyata et al., 1999). 
Dialysis-related amyloidosis is one of the most harmful osteoarticular complications with 
regard to the maintenance of daily activities and quality of life in patients undergoing long-
term dialysis therapy (Yamamoto et al., 2009). 
11. Hyperhomocysteinemia and endothelial dysfunction 
Hyperhomocysteinemia is present in the majority of patients with chronic kidney failure. 
They have a plasma concentration of homocysteine elevated 3 to 4 times above normal 
(Suliman et al., 2001). The causes are still not clear, but the possibilities include defective 
renal or extrarenal metabolism as a result of uremic toxicity (Perna et al., 2004). 
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In the general population, hyperhomocysteinemia is considered to be an independent risk 
factor for the development of cardiovascular disease. As mentioned above, reverse 
epidemiology of traditional cardiovascular risk factors occurs in patients with chronic 
kidney failure, so that increased homocysteine levels appear to be paradoxically associated 
with a better clinical outcome. The development of malnutrition-inflammation complex 
syndrome is responsible for this phenomenon. Plasma homocysteine concentration is higher 
in patients with normal nutritional status than in malnourished patients. Plasma 
homocysteine was inversely correlated with subjective global nutritional assessment and 
positively correlated with serum albumin and protein intake. Thus, serum albumin 
concentration is a strong determinant of plasma homocysteine concentration in patients 
with chronic kidney failure. 
On the other hand, the toxicity of homocysteine results from the structural modification of 
proteins and deoxyribonucleic acid (DNA). Disruption of DNA methylation has been 
demonstrated to occur as a result of hyperhomocysteinemia and is associated with vascular 
damage (Perna et al., 2005). Homocysteine could be a principal candidate for endothelial 
dysfunction in patients with chronic kidney failure. Hyperhomocysteinemia may impair 
endothelial function by the generation of oxygen species and decreased NO bioavailability. 
NO is produced by endothelial NO synthase and it has many positive vascular effects. It 
mediates normal endothelial and vessel wall functions including antithrombosis, 
endothelial permselectivity, and vasomotor tone. In addition, NO suppresses cellular 
proliferation (e.g., of vascular smooth muscle cells) and has a quenching effect on 
inflammation. The function of the endothelial NO synthase is impaired in patients with 
chronic kidney disease (Kone, 1997). However, the precise mechanisms underlying the link 
between hyperhomocysteinemia and impaired endothelial function in chronic kidney 
failure is not quite clear. Some authors propose that accumulation of asymmetric 
dimethylarginine (ADMA), an endogenous inhibitor of NO synthase, could be the missing 
connecting link. Homocysteine is produced during ADMA synthesis and can alter ADMA 
catabolism mainly by inhibiting dimethylarginine dimethylaminohydrolase (Dayal & Lentz, 
2005). ADMA levels are elevated in patients with chronic kidney disease, and ADMA 
should be considered to be a futher uremic toxin. In some studies, an increased level of 
ADMA has been identified as an independent predictor of mortality in patients with chronic 
kidney disease (Ravani et al., 2005; Cibulka et al., 2007). 
In any case, influence the endothelial function in chronic kidney failure may offer a novel 
strategy to reduce risk for cardiovascular disease. 
12. Conclusion 
In conclusion, it is necessary to emphasize the importance of searching actively for chronic 
kidney disease. Unfortunately, it is often overlooked in its earliest, most treatable stages. 
Guidelines from the National Kidney Foundation’s KDOQI recommend estimating GFR and 
screening for albuminuria in patients with risk factors for chronic kidney disease, including 
diabetes, hypertension, systemic illnesses, age greater than 60 years, and family history of 
chronic kidney disease. When chronic kidney disease is detected, an attempt should be 
made to identify and treat the underlying conditions as well as the secondary abnormalities. 
These goals include slowing disease progression, detecting and treating complications, and 
managing cardiovascular risk factors. Suitable treatment also includes attention to the 
influence of elevated blood pressure, malnutrition, anemia, hyperparathyroidism, insulin 
www.intechopen.com
 
Special Problems in Hemodialysis Patients 
 
164 
resistance, disorders of lipid metabolism, and acid–base balance. At the same time, it is 
necessary to continue research projects focused on other areas that may uncover new 
aspects of cardiometabolic risk and its influence in patients with chronic kidney disease. 
These areas include the development of malnutrition-inflammation complex syndrome, 
management of oxidative stress, and endothelium protection. Clearly, progress in 
management of cardiovascular disease in patients with chronic kidney disease will require 
collaboration with experts in the research and treatment of vascular disease. 
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